Epsametostat

Epsametostat
Clinical data
Other names	HH2853
Identifiers
	IUPAC name N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-6-methyl-1-(6-methylpyridazin-3-yl)-5-[(1R)-1-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]ethyl]indolizine-7-carboxamide;
CAS Number	2202678-06-4;
PubChem CID	134340937;
UNII	P8U5JF6NBY;
Chemical and physical data
Formula	C31H36F3N7O3
Molar mass	611.670 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NN=C(C=C1)C2=C3C=C(C(=C(N3C=C2)[C@@H](C)N4CCN(CC4)CC(F)(F)F)C)C(=O)NCC5=C(C=C(NC5=O)C)OC;
	InChI InChI=InChI=1S/C31H36F3N7O3/c1-18-6-7-25(38-37-18)22-8-9-41-26(22)15-23(29(42)35-16-24-27(44-5)14-19(2)36-30(24)43)20(3)28(41)21(4)40-12-10-39(11-13-40)17-31(32,33)34/h6-9,14-15,21H,10-13,16-17H2,1-5H3,(H,35,42)(H,36,43)/t21-/m1/s1; Key:BIABSPVTTUDBEO-OAQYLSRUSA-N;

Epsametostat is an investigational new drug that is being evaluated for the treatment of peripheral T-cell lymphoma. It is a EZH1/EZH2 inhibitor developed by Shanghai Haihe Pharmaceutical Research & Development Co., Ltd.^[1]^[2]^[3]

References

^ An R, Li YQ, Lin YL, Xu F, Li MM, Liu Z (February 2023). "EZH1/2 as targets for cancer therapy". Cancer Gene Therapy. 30 (2): 221–235. doi:10.1038/s41417-022-00555-1. PMID 36369341.
^ Wei L, Mei D, Hu S, Du S (August 2024). "Dual-target EZH2 inhibitor: latest advances in medicinal chemistry". Future Medicinal Chemistry. 16 (15): 1561–1582. doi:10.1080/17568919.2024.2380243. PMID 39082677.
^ "Epsametostat". PatSnap.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[An_2023-1] An R, Li YQ, Lin YL, Xu F, Li MM, Liu Z (February 2023). "EZH1/2 as targets for cancer therapy". Cancer Gene Therapy. 30 (2): 221–235. doi:10.1038/s41417-022-00555-1. PMID 36369341.

[Wei_2024-2] Wei L, Mei D, Hu S, Du S (August 2024). "Dual-target EZH2 inhibitor: latest advances in medicinal chemistry". Future Medicinal Chemistry. 16 (15): 1561–1582. doi:10.1080/17568919.2024.2380243. PMID 39082677.

[3] "Epsametostat". PatSnap.

[1]

[2]

[3]